Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 19/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946411 | 0.88 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL1947145 | 0.88 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL10285384 | 0.86 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL10285397 | 0.86 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL10241780 | 0.82 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL1949101 | 0.81 | CDK9 (0.60) | CDK9CCNT1 | |
| SCHEMBL1946808 | 0.81 | CDK9 (0.60) | CDK9CCNT1 | |
| SCHEMBL1945794 | 0.77 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL1946290 | 0.76 | CDK9 (0.57) | CDK9CCNT1 | |
| SCHEMBL12827082 | 0.76 | CDK9 (0.60) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK9 2660/4885CCNT1 3465/4885MAPK8 3276/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDK9 1734/4885CCNT1 3865/4885MAPK8 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.